What the business is, and whether it's a good one at a fair price.
Makes specialty chemicals across four operating segments — Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Pharma & Specialty Chemical intermediates (PASC) and Electrolyte Salts. In Q1 FY27 the four segments generated segment revenue of ₹428M (PTC), ₹578M (SDA), ₹584M (PASC) and ₹63M (Electrolyte Salts); PTC is positioned as a process-enabling chemistry technology and SDA serves emissions-control applications where Euro 7 implementation is translating into revenue. PASC covers pharma intermediates, with the first molecule entering commercial production in Q1 FY27 and three new molecules expected to add ₹70-80 crore in FY27. The Dahej manufacturing site is essentially saturated and a Dahej-III greenfield unit has been approved with groundbreaking on 20 July 2026, targeting about ₹300 crore peak revenue. The largest input cost is raw materials at 51.9% of revenue, with amines among those whose prices have risen 30-40% on geopolitical factors; most increases are being passed to customers.
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from TATVA CHIN PHARM CHEM LTD's filed financials and exchange disclosures
TATVA CHIN PHARM CHEM LTD is a Chemicals & Petrochemicals company listed on NSE and BSE, trading under the symbol TATVA.
Yes. Over the trailing twelve months TATVA CHIN PHARM CHEM LTD reported a net profit of ₹51 Cr on revenue of ₹556 Cr.
Yes. The dividend yield is 0.06% at the current price. It paid out 6% of its profit as dividend in FY26.
No. Debt stands at 0.15× equity, and it carries net debt of ₹115 Cr. That is lower than 53% of its 101 Specialty Chemicals peers.
On trailing P/E, TATVA CHIN PHARM CHEM LTD ranks 88 of 103 in Specialty Chemicals — cheaper than 15% of them, against an industry median of 23.4×. This is a position, not a valuation judgement.
On a typical session TATVA CHIN PHARM CHEM LTD moves 1.73% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by TATVA CHIN PHARM CHEM LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
